A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection (Q77726501)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

title

A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

author name string

Aiden A Flynn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Alan J Green

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

R Barbara Pedley

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Geoffrey M Boxer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Jason Dearling

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Rebecca Watson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Robert Boden

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Richard H J Begent

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 February 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

4 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

1249-1257

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Radioimmunodiagnosis and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Dose fractionation, dose rate and iso-effect relationships for normal tissue responses.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Dose-rate effects in targeted radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Radiobiological aspects of low dose rates in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Isoeffect models and fractionated radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Phage libraries for generation of clinically useful antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear--quadratic formulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Oxygen diffusion and the distribution of cellular radiosensitivity in tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Histological, epidemiological and clinical aspects of centroblastic-centrocytic lymphomas subdivided according to the “working formulation”

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Estimation of tumour hypoxic fraction from clinical data sets compatible with accelerated repopulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10293

7 January 2021

Identifiers

DOI

10.1002/CNCR.10293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11877753%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference